Asymptomatic Patients With Brugada ECG Pattern: Long-Term Prognosis From a Large Prospective Study.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
14 Nov 2023
Historique:
medline: 15 11 2023
pubmed: 13 10 2023
entrez: 13 10 2023
Statut: ppublish

Résumé

Brugada syndrome poses significant challenges in terms of risk stratification and management, particularly for asymptomatic patients who comprise the majority of individuals exhibiting Brugada ECG pattern (BrECG). The aim of this study was to evaluate the long-term prognosis of a large cohort of asymptomatic patients with BrECG. Asymptomatic patients with BrECG (1149) were consecutively collected from 2 Italian centers and followed-up at least annually for 2 to 22 years. For the 539 asymptomatic patients (men, 433 [80%]; mean age, 46±13 years) with spontaneous type 1 documented on baseline ECG (87%) or 12-lead 24-hour Holter monitoring (13%), an electrophysiologic study (EPS) was proposed; for the 610 patients with drug-induced-only type 1 (men, 420 [69%]; mean age, 44±14 years), multiple ECGs and 12-lead Holter were advised in order to detect the occurrence of a spontaneous type-1 BrECG. Arrhythmic events were defined as sudden death or documented ventricular fibrillation or tachycardia. Median follow-up was 6 (4-9) years. Seventeen (1.5%) arrhythmic events occurred in the overall asymptomatic population (corresponding to an event-rate of 0.2% per year), including 16 of 539 (0.4% per year) in patients with spontaneous type-1 BrECG and 1 of 610 in those with drug-induced type-1 BrECG (0.03% per year; The entire population of asymptomatic patients with BrECG exhibits a relatively low event rate per year, which is important in view of the long life expectancy of these young patients. The presence of spontaneous type-1 BrECG associated with positive EPS identifies a subgroup at higher risk. Asymptomatic patients with drug-induced-only BrECG have a minimal arrhythmic risk, but ongoing follow-up with 12-lead Holter monitoring is recommended to detect the appearance of spontaneous type-1 BrECG pattern.

Sections du résumé

BACKGROUND BACKGROUND
Brugada syndrome poses significant challenges in terms of risk stratification and management, particularly for asymptomatic patients who comprise the majority of individuals exhibiting Brugada ECG pattern (BrECG). The aim of this study was to evaluate the long-term prognosis of a large cohort of asymptomatic patients with BrECG.
METHODS METHODS
Asymptomatic patients with BrECG (1149) were consecutively collected from 2 Italian centers and followed-up at least annually for 2 to 22 years. For the 539 asymptomatic patients (men, 433 [80%]; mean age, 46±13 years) with spontaneous type 1 documented on baseline ECG (87%) or 12-lead 24-hour Holter monitoring (13%), an electrophysiologic study (EPS) was proposed; for the 610 patients with drug-induced-only type 1 (men, 420 [69%]; mean age, 44±14 years), multiple ECGs and 12-lead Holter were advised in order to detect the occurrence of a spontaneous type-1 BrECG. Arrhythmic events were defined as sudden death or documented ventricular fibrillation or tachycardia.
RESULTS RESULTS
Median follow-up was 6 (4-9) years. Seventeen (1.5%) arrhythmic events occurred in the overall asymptomatic population (corresponding to an event-rate of 0.2% per year), including 16 of 539 (0.4% per year) in patients with spontaneous type-1 BrECG and 1 of 610 in those with drug-induced type-1 BrECG (0.03% per year;
CONCLUSIONS CONCLUSIONS
The entire population of asymptomatic patients with BrECG exhibits a relatively low event rate per year, which is important in view of the long life expectancy of these young patients. The presence of spontaneous type-1 BrECG associated with positive EPS identifies a subgroup at higher risk. Asymptomatic patients with drug-induced-only BrECG have a minimal arrhythmic risk, but ongoing follow-up with 12-lead Holter monitoring is recommended to detect the appearance of spontaneous type-1 BrECG pattern.

Identifiants

pubmed: 37830188
doi: 10.1161/CIRCULATIONAHA.123.064689
pmc: PMC10637308
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1543-1555

Commentaires et corrections

Type : CommentIn

Auteurs

Fiorenzo Gaita (F)

Maria Pia Hospital, GVM Care and Research, Turin, Italy (F.G.).
Departments of Medical Sciences (F.G., C.G., M.M., A.S., G.B., G.M.D.F.), University of Turin, Italy.

Natascia Cerrato (N)

Division of Cardiology, Cardinal G. Massaia Hospital, Asti, Italy (N.C., D.C., M.S.).

Carla Giustetto (C)

Departments of Medical Sciences (F.G., C.G., M.M., A.S., G.B., G.M.D.F.), University of Turin, Italy.
Division of Cardiology, Cardiovascular and Thoracic Department, "Città della Salute e della Scienza" Hospital, Turin, Italy (C.G., M.M., A.S., G.B., G.M.D.F.).

Annamaria Martino (A)

Division of Cardiology, Policlinico Casilino, Rome, Italy (A.M., E.S., C.C., S.C., M.D.M., L.C.).

Laura Bergamasco (L)

Surgical Sciences (L.Bergamasco), University of Turin, Italy.

Michele Millesimo (M)

Departments of Medical Sciences (F.G., C.G., M.M., A.S., G.B., G.M.D.F.), University of Turin, Italy.
Division of Cardiology, Cardiovascular and Thoracic Department, "Città della Salute e della Scienza" Hospital, Turin, Italy (C.G., M.M., A.S., G.B., G.M.D.F.).

Lorella Barbonaglia (L)

Division of Cardiology, Sant'Andrea Hospital, Vercelli, Italy (L.Barbonaglia., F.R.).

Paula Carvalho (P)

Division of Cardiology, San Luigi Gonzaga Hospital, Orbassano, Italy (P.C.).

Domenico Caponi (D)

Division of Cardiology, Cardinal G. Massaia Hospital, Asti, Italy (N.C., D.C., M.S.).

Andrea Saglietto (A)

Departments of Medical Sciences (F.G., C.G., M.M., A.S., G.B., G.M.D.F.), University of Turin, Italy.
Division of Cardiology, Cardiovascular and Thoracic Department, "Città della Salute e della Scienza" Hospital, Turin, Italy (C.G., M.M., A.S., G.B., G.M.D.F.).

Giacomo Bonacchi (G)

Departments of Medical Sciences (F.G., C.G., M.M., A.S., G.B., G.M.D.F.), University of Turin, Italy.
Division of Cardiology, Cardiovascular and Thoracic Department, "Città della Salute e della Scienza" Hospital, Turin, Italy (C.G., M.M., A.S., G.B., G.M.D.F.).

Francesca Bianchi (F)

Division of Cardiology, A.O. Ordine Mauriziano, Turin, Italy (F.B., G.M.).

Elisa Silvetti (E)

Division of Cardiology, Policlinico Casilino, Rome, Italy (A.M., E.S., C.C., S.C., M.D.M., L.C.).

Cinzia Crescenzi (C)

Division of Cardiology, Policlinico Casilino, Rome, Italy (A.M., E.S., C.C., S.C., M.D.M., L.C.).

Stefano Canestrelli (S)

Division of Cardiology, Policlinico Casilino, Rome, Italy (A.M., E.S., C.C., S.C., M.D.M., L.C.).

Melissa De Maio (M)

Division of Cardiology, Policlinico Casilino, Rome, Italy (A.M., E.S., C.C., S.C., M.D.M., L.C.).

Gaetano Maria De Ferrari (GM)

Departments of Medical Sciences (F.G., C.G., M.M., A.S., G.B., G.M.D.F.), University of Turin, Italy.
Division of Cardiology, Cardiovascular and Thoracic Department, "Città della Salute e della Scienza" Hospital, Turin, Italy (C.G., M.M., A.S., G.B., G.M.D.F.).

Giuseppe Musumeci (G)

Division of Cardiology, A.O. Ordine Mauriziano, Turin, Italy (F.B., G.M.).

Francesco Rametta (F)

Division of Cardiology, Sant'Andrea Hospital, Vercelli, Italy (L.Barbonaglia., F.R.).

Marco Scaglione (M)

Division of Cardiology, Cardinal G. Massaia Hospital, Asti, Italy (N.C., D.C., M.S.).

Leonardo Calò (L)

Division of Cardiology, Policlinico Casilino, Rome, Italy (A.M., E.S., C.C., S.C., M.D.M., L.C.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH